First-in-human phase I study of EMB-02, a bispecific antibody targeting PD-1 and LAG-3 in patients with advanced solid tumors
Daphne Day(Monash Health), Jun Guo(Hebei Medical University)
Cited by 7
Related Papers
Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions
|Frontiers in Immunology|2021|163
Phosphorylation of mTOR and S6RP predicts the efficacy of everolimus in patients with metastatic renal cell carcinoma
|BMC Cancer|2014|54
RBCK1 promotes p53 degradation via ubiquitination in renal cell carcinoma
|Cell Death and Disease|2019|50